Drugs / Lipofundin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04277923 | Feb 2020 → Aug 2021 | pulmonary immaturity | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04347902 | Jan 2016 → Mar 2020 | intestinal failure–associated liver disease, liver failure | Stanley Dudrick's Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01683162 | Jul → Dec 2012 | pulmonary immaturity | Wei Cai | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipofundin | “Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)” NCT04347902 ↗ |
| Modality | Other / unclassified | “the MCT/LCT lipid emulsion is Lipofundin.” NCT04277923 ↗ |